Amgen 2002 Annual Report Download - page 11

Download and view the complete annual report

Please find page 11 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Page 9
The year 2002 was one of substantial growth and
accomplishment for Amgen. We served more patients
than ever, launched several new potential blockbuster
products, delivered financially, gained experience
in highly competitive commercial markets, added
thousands of new staff members, advanced and grew
the pipeline, and invested for the future. We are
proud of these results and the balance of this report
provides details.
In a year of such accomplishment, it would be easy
to go on for pages about our achievements, but there
was one event in 2002 I would like to focus on here
that, as much as any other, captures the spirit and pur-
pose of Amgen. And the picture on the facing page
tells some of that story. The people pictured with me
in the photo are the leaders who were instrumental
in securing FDA approval for our Rhode Island
ENBREL
®
(etanercept) manufacturing facility. This
was an enormous task. We cannot say enough about
the skill, dedication, and determination of the team
that made the facility ready for a successful FDA
inspection. The teamwork they and hundreds of
others across Amgen and our new colleagues from
Immunex Corporation displayed to make this vital
drug available to patients spoke volumes about us –
united in purpose to provide drugs to patients that
will dramatically improve their lives. ENBREL
®
is
one of those drugs. Bringing this facility on line
relieved a severe supply shortfall that prevented
patients who needed the drug from getting it. Today
ENBREL
®
is widely and easily available to address
Opposite page: ENBREL
®
manufacturing facility in Rhode Island. Pictured left to right are Roop Kumar, Kimball Hall,
Amgen’s CEO Kevin Sharer, Jay Marshall (seated), Tony Pankau, Jerry McAndrews, and Kathleen Retterson.
the severe illnesses of rheumatoid arthritis and
psoriatic arthritis.
The ENBREL
®
facility story is part of a larger story
of the combination of two great companies: Amgen
and Immunex. Many teams and hundreds of leaders
worked for many months to make this combina-
tion successful. We are pleased with the results.
Scientific programs were combined and advanced,
organizations were brought together, key Immunex
leaders filled vital Amgen jobs, the clinical develop-
ment of ENBREL
®
continued successfully across a
growing number of indications, and construction
was advanced on both the Seattle research site over-
looking Puget Sound and the vital additional
ENBREL
®
manufacturing facility in Rhode Island.
This all happened as Amgen delivered across the
Letter to Stockholders
Amgen values
●Be science-based
●Compete intensely and win
●Create value for patients, staff,
and stockholders
●Be ethical
●Trust and respect each other
●Ensure quality
●Work in teams
●Collaborate, communicate, and
be accountable